New Zealand markets open in 6 hours 17 minutes
  • NZX 50

    11,654.56
    +102.52 (+0.89%)
     
  • NZD/USD

    0.6387
    +0.0089 (+1.42%)
     
  • ALL ORDS

    7,554.00
    +73.30 (+0.98%)
     
  • OIL

    82.71
    +2.16 (+2.68%)
     
  • GOLD

    1,813.80
    +53.90 (+3.06%)
     

Pipeline Therapeutics Announces Participation in Upcoming Investor Conferences

SAN DIEGO, October 04, 2022--(BUSINESS WIRE)--Pipeline Therapeutics, a clinical-stage biopharmaceutical company pioneering precision neuroregeneration, announced today that management will participate in the following investor conferences during October 2022:

  • Cantor Fitzgerald Neurology & Psychiatry Conference, October 6, in San Francisco, CA

  • BMO Life Sciences Private Company Showcase October 13, in New York, NY

  • Oppenheimer’s Private Company Showcase, October 17-18, in Palo Alto, CA

  • 2nd Annual Needham Biotech Private Company Virtual 1x1 Forum, October 18-19

  • Bank of America Private Company Showcase, October 20, in Boston, MA

About Pipeline Therapeutics

Pipeline Therapeutics is a clinical-stage biopharmaceutical company pioneering the development and commercialization of first-in-class therapies for precision neuroregeneration including myelin restoration, synaptogenesis and axonal repair. The Company has a broad pipeline of programs to address multiple CNS disorders. Its flagship program, PIPE-307, has completed two Phase 1 clinical trials - a SAD/MAD study and a PET study - in healthy volunteers, and has received Investigational New Drug clearance from the Food and Drug Administration to initiate clinical development in relapsing-remitting MS patients.

For more information, please visit www.pipelinetherapeutics.com and engage with us on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221004005448/en/

Contacts

Company Contact:

Peter Slover
CFO
ir@pipeline-tx.com

Investor Contact:

Amy Conrad
858-914-1962
amy@juniper-point.com